1317 ET - Hims & Hers is hoping to take advantage of an FDA rule to be able to keep selling compounded versions of weight-loss drugs, even after the GLP-1 shortage has ended, Needham analyst Ryan MacDonald tells WSJ. The personalization exemption rule allows companies to sell compounds if they are personalizing the treatment for a patient; for example, if the patient needs to take an oral form instead of an injection. Hims hopes it can keep offering personalized compounds, as compounded drugs make up a significant portion of its weight-loss revenue, MacDonald says. But if the FDA finds this illegal, the company may be challenged to meet revenue goals, MacDonald says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:17 ET (17:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。